Stockscreener 앱 받기
14.55
2.97%
0.42
시간 외 거래:
14.55
전일 마감가:
$14.13
열려 있는:
$14.3
하루 거래량:
2.39M
Relative Volume:
1.97
시가총액:
$1.48B
수익:
-
순이익/손실:
$-294.51M
주가수익비율:
-4.0871
EPS:
-3.56
순현금흐름:
$-244.42M
1주 성능:
-3.00%
1개월 성능:
-39.35%
6개월 성능:
-64.91%
1년 성능:
-6.85%
1일 변동 폭
$13.99
$14.73
1주일 범위
$13.99
$15.80
52주 변동 폭
$13.99
$47.45
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
DYN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
14.55 | 1.48B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
Oppenheimer maintains Dyne stock Outperform with $60 target - MSN
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 - GlobeNewswire
Dyne stock gains on FDA fast track tag (DYN:NASDAQ) - Seeking Alpha
Dyne Enjoys Fast Track Status for New Treatment - Baystreet.ca
JPMorgan Chase & Co. Grows Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Hits New 1-Year Low – Here’s Why - Defense World
Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.7%What's Next? - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Reaches New 1-Year LowWhat's Next? - MarketBeat
How To Trade (DYN) - Stock Traders Daily
Dyne Therapeutics' (DYN) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Dyne Therapeutics Provides Updates on Clinical Trials in Recent 8-K Filing - Defense World
Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low – Time to Sell? - Defense World
HC Wainwright Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN) - Defense World
Chardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potenti - Investing.com South Africa
Dyne Therapeutics (NASDAQ:DYN) Receives "Buy" Rating from Chardan Capital - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Earns "Buy" Rating from HC Wainwright - MarketBeat
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday? - Benzinga
Dyne Therapeutics stock tumbles following trial data By Investing.com - Investing.com Nigeria
Dyne Therapeutics (NASDAQ:DYN) Shares Gap DownHere's Why - MarketBeat
Dyne Therapeutics stock tumbles following trial data - Investing.com
Why Dyne Therapeutics Shares Are Shifting - TipRanks
Dyne Therapeutics Advances Clinical Trials for DM1 and DMD - TipRanks
Dyne Therapeutics Reports New Clinical Data Showing - GlobeNewswire
Dyne Therapeutics' DM1 Treatment Shows Breakthrough Results, Plans Accelerated FDA Filing - StockTitan
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Dyne Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Dyne Therapeutics shares jump ahead of clinical data review By Investing.com - Investing.com Canada
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET - The Manila Times
Dyne Therapeutics to Host Investor Conference Call and - GlobeNewswire
Dyne Therapeutics Sets Key Date for ACHIEVE Trial Data Release in Early 2025 - StockTitan
Principal Financial Group Inc. Reduces Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
(DYN) Proactive Strategies - Stock Traders Daily
Dyne Therapeutics (NASDAQ:DYN) Trading Down 3.7%Here's What Happened - MarketBeat
Dyne Therapeutics initiated with Outperform at Baird - MSN
Dyne Therapeutics (NASDAQ:DYN) Shares Up 10.4%What's Next? - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of "Buy" by Analysts - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of “Buy” from Analysts - Defense World
Where are the Opportunities in (DYN) - Stock Traders Daily
Geode Capital Management LLC Acquires 84,760 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Barclays PLC Purchases 128,246 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Wellington Management Group LLP Reduces Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Franklin Resources Inc. Cuts Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up – Still a Buy? - Defense World
State Street Corp Raises Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Shares Gap UpWhat's Next? - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Upgraded at Raymond James - MarketBeat
How to Take Advantage of moves in (DYN) - Stock Traders Daily
Baird Initiates Coverage of Dyne Therapeutics (DYN) with Outperform Recommendation - MSN
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Robert W. Baird - MarketBeat
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):